```
=> d his

     (FILE 'HOME' ENTERED AT 21:05:11 ON 23 OCT 2007)

     FILE 'REGISTRY' ENTERED AT 21:05:22 ON 23 OCT 2007
L1             STRUCTURE UPLOADED
L2        508589 S NCNC2/ESS (S) C6/ESS
L3             SCREEN 1841
L4            50 S (L1 AND L3) SAM SUB=L2
L5          4672 S (L1 AND L3) SSS FULL SUB=L2
               SAV TEM L5 BRD564184/A
L6             STRUCTURE UPLOADED
L7             STRUCTURE UPLOADED
L8            50 S L6 SAM SUB=L5
L9          4380 S L6 SSS FULL SUB=L5
L10            2 S L7 SAM SUB=L9
L11           68 S L7 SSS FULL SUB=L9
               SAV TEM L11 ELE564184/A

     FILE 'CAPLUS' ENTERED AT 21:08:11 ON 23 OCT 2007
L12            4 S L11

     FILE 'REGISTRY' ENTERED AT 21:08:21 ON 23 OCT 2007

=> d l1
L1 HAS NO ANSWERS
L1             STR
```




```
G1 C,O,S,N


Structure attributes must be viewed using STN Express query preparation.


=> d l6
L6 HAS NO ANSWERS
L6             STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> d l7
L7 HAS NO ANSWERS
L7             STR
```



Structure attributes must be viewed using STN Express query preparation.

C:\Program Files\Stnexp\Queries\10564184-broad-F.str





chain nodes :
1 2 4 5 13
ring nodes :
6 7 8 9 10 11
chain bonds :
1-2 2-4 2-5 5-7
ring bonds :
6-7 6-11 7-8 8-9 9-10 10-11
exact/norm bonds :
1-2 2-4 2-5 5-7
normalized bonds :
6-7 6-11 7-8 8-9 9-10 10-11
isolated ring systems :
containing 6 :

G1:C,O,S,N

Match level :
1:Atom 2:CLASS 4:CLASS 5:CLASS 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
13:CLASS 14:Atom

C:\Program Files\Stnexp\Queries\10564184-elected-F-1.str





chain nodes :
1 2 3 4 12
ring nodes :
5 6 7 8 9 10
chain bonds :
1-2 2-3 2-4 4-6
ring bonds :
5-6 5-10 6-7 7-8 8-9 9-10
exact/norm bonds :
1-2 2-3 2-4 4-6
normalized bonds :
5-6 5-10 6-7 7-8 8-9 9-10
isolated ring systems :
containing 5 :

Match level :
1:Atom 2:CLASS 3:CLASS 4:CLASS 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
12:CLASS 13:Atom

C:\Program Files\Stnexp\Queries\10564184-elected-F-2.str





chain nodes :
14
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12
chain bonds :
12-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
exact/norm bonds :
12-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 : 7 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 14:CLASS 15:Atom

=> d l12 tot bib abs hitstr

L12 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:733579 CAPLUS Full-text
DN 147:143461
TI Preparation of novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases
IN Lang, Hengyuan; Gahman, Timothy C.; Herbert, Mark R.; Zhao, Cunxiang; Wasti, Paul L.; Davis, Robert L.
PA Kalypsys, Inc., USA
SO PCT Int. Appl., 77pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007076474	A1	20070705	WO 2006-US62552	20061222
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 2007155746	A1	20070705	US 2006-615907	20061222
PRAI US 2005-753601P	P	20051223		
US 2006-851490P	P	20061013		

OS MARPAT 147:143461
GI



I II

AB Title compds. I [X1-4 independently = CR1 and N, wherein one or two of X1-4 = N; R1 = H, (un)substituted alkenyl, alkoxy, alkyl, alkynyl, etc.; R2 = (un)substituted aryl , carboxy, ester, etc.; A and C independently = (un)substituted Ph, pyridine, benzothiazole, benzofuran, benzothiophene, and numerous other ring systems; B = -NHCOCH2- or -NHCO-], and their pharmaceutically acceptable salts, esters, and prodrugs, are prepared and disclosed as inhibitors of protein kinases, including B-Raf and several

receptor tyrosine and cytoplasmic tyrosine kinases. Thus, e.g., II was prepared by acylation of 4-(2-[1,3,4]oxadiazol-2-ylpyridin-3-yloxy)phenylamine (preparation given) with 4-fluoro-3-trifluoromethylphenylacetic acid. The invention compds. are evaluated for their inhibitory activity in in vitro B-Raf/MeK1 composite kinase assay, VEGFR2 and PDGFRβ kinase assays. For instance, II demonstrated IC50 value ≤ 10 μM in in vitro VEGFR2 assay. The invention also provides methods of modulating of protein kinase activity in a human or animal subject for the treatment diseases such as cancers.

IT 943632-30-2P, N-[3-[2-(1-Methyl-1H-pyrazol-4-yl)pyridin-4-yloxy]phenyl]-1H-benzo[d]imidazole-5-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases)

RN 943632-30-2 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2,3-dihydro-N-[3-[[2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl]oxy]phenyl]- (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:538689 CAPLUS Full-text
DN 146:521800
TI Heterocyclic compounds as tyrosine kinase modulators and their preparation, pharmaceutical compositions and use in the treatment of diseases
IN Anikin, Alexey Vyacheslavovich; Gantla, Vidyasagar Reddy; Gregor, Vlad Edward; Jiang, Luyong; Liu, Yahua; Mcgee, Danny Peter Claude; Mikel, Charles Chamchoumis; Pickens, Jason Conrad; Webb, Thomas Roy; Zheng, Yan; Zhu, Tong; Kadushkin, Aleksander; Zozulya, Sergey; Chucholowski, Alexander; Mcgrath, Douglas Eric; Sviridov, Sergey
PA Chembridge Research Laboratories, Inc., USA
SO PCT Int. Appl., 385pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007056155	A1	20070518	WO 2006-US42982	20061102
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2005-734050P P 20051103
OS MARPAT 146:521800
GI



I II

AB The invention provides compds. of formula I and related compds., capable of modulating tyrosine kinases, compns. comprising the compds. and methods of their use. Compds. of formula I wherein R1 is (un)substituted heterocyclyl, (un)substituted alkyl, (un)substituted sulfonyl, acyl, etc.; R2 is H, lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkylalkyl, (un)substituted (hetero)aryl(alkyl), heterocycloalkyl, etc.; Q1, Q2, Q3 and Q4 are independently. C1-5 alkyl; and their stereoisomers, tautomers, salts, hydrates and prodrugs thereof, are claimed. Example compound II was prepared by amidation of 2-[2-hydroxy-5-(2-methoxypyridin-3- yl)phenyl]benzimidazole-5-carboxylic acid with 1-methoxy-2-propylamine. All the invention compds. were evaluated for their tyrosine kinase modulatory activity (some data given).

IT 936932-26-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of heterocyclic compds. as tyrosine kinase modulators and their use in the treatment of diseases)

RN 936932-26-2 CAPLUS
CN 1H-Benzimidazole-6-carboxamide, 2-[2-hydroxy-5-(2-methoxy-3-pyridinyl)phenyl]-N-[2-(3-pyridinyloxy)phenyl]- (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1260610 CAPLUS Full-text
DN 144:22946
TI Preparation of nitrogen-heteroaryl-containing protein kinase modulators for use against cancer and other diseases
IN Geuns-Meyer, Stephanie D.; Hodous, Brian L.; Chaffee, Stuart C.; Tempest, Paul A.; Olivieri, Philip R.; Johnson, Rebecca E.; Albrecht, Brian K.; Patel, Vinod F.; Cee, Victor J.; Kim, Joseph L.; Bellon, Steven; Zhu, Xiaotian; Cheng, Yuan; Xi, Ning; Romero, Karina; Nguyen, Hanh Nho; Deak, Holly L.
PA Amgen Inc., USA
SO PCT Int. Appl., 540 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005113494	A2	20051201	WO 2005-US16346	20050509
WO 2005113494	A3	20060316		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2005245386	A1	20051201	AU 2005-245386	20050509
CA 2564355	A1	20051201	CA 2005-2564355	20050509
US 2006009453	A1	20060112	US 2005-126000	20050509
EP 1751136	A2	20070214	EP 2005-779977	20050509
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			
PRAI US 2004-569193P	P	20040507		
WO 2005-US16346	W	20050509		

OS MARPAT 144:22946
GI



I



II

AB The present invention relates to nitrogen-heteroaryl-containing compds. (shown as I; variables defined below; e.g. 4-fluoro-3-[[3-(pyrimidin-4-yl)pyridin- 2-yl]amino]-N-[3-[(tetrahydrofuran-2-yl)methoxy]-5- trifluoromethylphenyl]benzamide (shown as II)) and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of these kinases. For example, the compds. are capable of modulating kinase enzymes thereby influencing the process of angiogenesis and treating angiogenesis-related diseases and other proliferative disorders, including cancer and inflammation. The invention also includes pharmaceutical compns., including the compds., and methods of treating disease states related to the activity of protein kinases. For I: A is N or CR10; B is N or CR11; D is N or CR12; E is N or CH; G is NR13, O, S, C(O), S(O), SO2, CR13R13 or CR13R14; H1 is N or CR5; H2 is N or CR6; H3 is N or CR7; H4 is N or CR5; H5 is N or CR9; R1 is H, halo, haloalkyl, NO2, CN, NR13R13, OR13, SR13 (CHR13)nR13, or R15; alternatively R1 taken together with R10 forms a partially or fully unsatd. 5- or 6-membered ring of C atoms optionally including 1-3 heteroatoms = O, N and S, and the ring (un)substituted; R2 is H, halo, haloalkyl, oxo, NO2, CN, SR13, et al.; each of R3 and R4, independently, is H, halo, haloalkyl, oxo, NO2, CN, SR13, et al.; addnl. details including provisos are given in the claims. Although the methods of preparation are not claimed, prepns. and/or characterization data for >1200 examples of I and intermediates are included. For example, II was prepared in 2 steps starting with condensation of 4-(2-chloropyridin-3- yl)pyrimidine (preparation given) with 3-amino-4-fluorobenzoic acid in Et3N-TFA to give 4-fluoro-3-[[3-(pyrimidin-4-yl)pyridin-2-yl]amino]benzoic acid, which was condensed with [3-[(tetrahydrofuran-2-yl)methoxy]-5- trifluoromethylphenyl]amine using EDC and DMAP in DMF.

IT 870231-32-6P, N-[3-Methyl-4-[[3-[2-(methylamino)-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]-1H-benzimidazole-5-carboxamide 870231-37-1P , 2-Methyl-N-[3-methyl-4-[[3-[2-(methylamino)-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]-1H-benzimidazole-5-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of nitrogen-heteroaryl-containing protein kinase
modulators for use against cancer and other diseases)

RN 870231-32-6 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, N-[3-methyl-4-[[3-[2-(methylamino)-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 870231-37-1 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-methyl-N-[3-methyl-4-[[3-[2-(methylamino)-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]- (9CI) (CA INDEX NAME)



L2 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:55061 CAPLUS Full-text
DN 142:134603
TI A preparation of benzimidazolecarboxamide derivatives, useful as raf-kinase inhibitors
IN Buchstaller, Hans-Peter; Wiesner, Matthias; Zenke, Frank; Amendt, Christiane; Grell, Matthias; Sirrenberg, Christian
PA Merck Patent GmbH, Germany
SO PCT Int. Appl., 184 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005004863	A1	20050120	WO 2004-EP6337	20040611
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

	AU 2004255402	A1	20050120	AU 2004-255402	20040611
	CA 2531856	A1	20050120	CA 2004-2531856	20040611
	EP 1643991	A1	20060412	EP 2004-739826	20040611
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	JP 2007506676	T	20070322	JP 2006-519782	20040611
	US 2007093532	A1	20070426	US 2006-564184	20060807
PRAI	EP 2003-15583	A	20030711		
	WO 2004-EP6337	W	20040611		

OS MARPAT 142:134603
GI



I

II

AB The invention relates to a preparation of benzimidazolecarboxamide derivs. of formula I [wherein: R1 is 0 to 5 independent substituents selected from H, cycloalkyl, halogen, CH2-halogen, or (CH2)0-5-CN, etc.; R2 and R3 are independently selected from H, (cyclo)alkyl, alkoxy, or SO2-(cyclo)alkyl, etc.; R4 is 1 to 5 substituted phenyl; Y is O, S, or C(CN)2, etc.], useful as raf-kinase inhibitors. For instance, benzimidazolecarboxamide derivative of formula II was prepared via amidation of 5-chlorobenzimidazolecarboxylic acid by 4-(4-pyridinyloxy)phenylamine with a yield of 75%. The preferred compound of the invention are raf-kinase inhibitors and showed IC50 values in the range of 100 μM or below.

IT 827042-67-1P 827042-68-2P 827042-69-3P
827042-70-6P 827042-71-7P 827042-72-8P
827042-73-9P 827042-74-0P 827042-75-1P
827042-76-2P 827043-77-3P 827043-78-4P
827042-79-5P 827042-80-8P 827042-81-9P
827042-82-0P 827042-83-1P 827042-84-2P
827042-85-3P 827042-86-4P 827042-87-5P
827042-88-6P 827042-89-7P 827042-90-0P
827042-91-1P 827042-92-2P 827042-93-3P
827042-94-4P 827042-95-5P 827042-96-6P
827042-97-7P 827043-98-8P 827042-99-9P
827043-00-5P 827043-01-6P 827042-02-7P
827043-02-8P 827043-04-9P 827043-05-0P
827043-06-1P 827043-07-2P 827042-08-3P
827043-09-4P 827043-10-7P 827043-11-8P
827043-12-9P 827043-13-0P 827043-14-1P
827043-15-2P 827043-16-3P 827043-17-4P
827043-18-5P 827043-19-6P 827043-20-9P
827043-21-0P 827043-22-1P 827043-23-2P

827043-24-3P 827043-25-4P 827043-26-5P
827043-27-6P 827043-28-7P 827043-31-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzimidazolecarboxamide derivs. useful as raf-kinase inhibitors)

RN 827042-67-1 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 5-chloro-N-[4-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 827042-68-2 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, N-[4-(4-pyridinyloxy)phenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 827042-69-3 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 5-chloro-4-methyl-N-[4-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 827042-70-6 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 4-bromo-N-[4-(4-pyridinyloxy)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 827042-71-7 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 5-chloro-N-[4-(4-pyridinyloxy)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 827042-72-8 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 4-methyl-N-[4-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 827042-73-9 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 4-chloro-N-[4-(4-pyridinyloxy)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 827042-74-0 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 5-chloro-6-methyl-N-[4-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 827042-75-1 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, N-[4-(4-pyridinyloxy)phenyl]-4,6-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 827042-76-2 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 5,6-dichloro-N-[4-(4-pyridinyloxy)phenyl]- (CA INDEX NAME)



RN 827042-77-3 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 5-methyl-N-[4-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 827042-78-4 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, N-[4-(4-pyridinyloxy)phenyl]- (CA INDEX NAME)



RN 827042-79-5 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 5-chloro-N-[4-(3-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 827042-80-8 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, N-[4-(3-pyridinyloxy)phenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 827042-81-9 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 5-chloro-4-methyl-N-[4-(3-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 827042-82-0 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 4-bromo-N-[4-(3-pyridinyloxy)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 827042-83-1 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 5-chloro-N-[4-(3-pyridinyloxy)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 827042-84-2 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 4-methyl-N-[4-(3-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 827042-85-3 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 4-chloro-N-[4-(3-pyridinyloxy)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 827042-86-4 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 5-chloro-6-methyl-N-[4-(3-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 827042-87-5 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, N-[4-(3-pyridinyloxy)phenyl]-4,6-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 827042-88-6 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 5,6-dichloro-N-[4-(3-pyridinyloxy)phenyl]- (CA INDEX NAME)



RN 827042-89-7 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 5-methyl-N-[4-(3-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 827042-90-0 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, N-[4-(3-pyridinyloxy)phenyl]- (CA INDEX NAME)



RN 827042-91-1 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 5-chloro-N-[3-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 827042-92-2 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, N-[3-(4-pyridinyloxy)phenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 827042-93-3 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 5-chloro-4-methyl-N-[3-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 827042-94-4 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 4-bromo-N-[3-(4-pyridinyloxy)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 827042-95-5 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 5-chloro-N-[3-(4-pyridinyloxy)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 827042-96-6 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 4-methyl-N-[3-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 827042-97-7 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 4-chloro-N-[3-(4-pyridinyloxy)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 827042-98-8 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 5-chloro-6-methyl-N-[3-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 827042-99-9 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, N-[3-(4-pyridinyloxy)phenyl]-4,6-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 827043-00-5 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 5-methyl-N-[3-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 827043-01-6 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, N-[3-(4-pyridinyloxy)phenyl]- (CA INDEX NAME)



RN 827043-02-7 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 4,5-dimethyl-N-[3-(4-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 827043-03-8 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, N-[3-(4-pyridinyloxy)phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 827043-04-9 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 5-chloro-N-[3-(3-pyridinyloxy)phenyl]-

(9CI) (CA INDEX NAME)



RN 827043-05-0 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, N-[3-(3-pyridinyloxy)phenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 827043-06-1 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 5-chloro-4-methyl-N-[3-(3-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 827043-07-2 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 4-bromo-N-[3-(3-pyridinyloxy)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 827043-08-3 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 5-chloro-N-[3-(3-pyridinyloxy)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 827043-09-4 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 4-methyl-N-[3-(3-pyridinyloxy)phenyl]-(9CI) (CA INDEX NAME)



RN 827043-10-7 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 4-chloro-N-[3-(3-pyridinyloxy)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 827043-11-8 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 5-chloro-6-methyl-N-[3-(3-pyridinyloxy)phenyl]- (9CI) (CA INDEX NAME)



RN 827043-12-9 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, N-[3-(3-pyridinyloxy)phenyl]-4,6-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 827043-13-0 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 5-methyl-N-[3-(3-pyridinyloxy)phenyl]-(9CI) (CA INDEX NAME)



RN 827043-14-1 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, N-[3-(3-pyridinyloxy)phenyl]- (CA INDEX NAME)



RN 827043-15-2 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 4,5-dimethyl-N-[3-(3-pyridinyloxy)phenyl]-(9CI) (CA INDEX NAME)



RN 827043-16-3 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, N-[4-(4-pyridinylmethyl)phenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 827043-17-4 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 5-chloro-4-methyl-N-[4-(4-

pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 827043-18-5 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 4-bromo-N-[4-(4-pyridinylmethyl)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 827043-19-6 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 5-chloro-N-[4-(4-pyridinylmethyl)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 827043-20-9 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 4-methyl-N-[4-(4-pyridinylmethyl)phenyl]-(9CI) (CA INDEX NAME)



RN 827043-21-0 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 4-chloro-N-[4-(4-pyridinylmethyl)phenyl]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 827043-22-1 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 5-chloro-6-methyl-N-[4-(4-pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 827043-23-2 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 5,6-dichloro-N-[4-(4-pyridinylmethyl)phenyl]- (CA INDEX NAME)



RN 827043-24-3 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, 5-methyl-N-[4-(4-pyridinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 827043-25-4 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, N-[4-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]phenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 827043-26-5 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, N-[3-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]phenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 827043-27-6 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, N-[3-[[2-[(methylamino)carbonyl]-4-pyridinyl]oxy]phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 827043-28-7 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, N-[3-[[6-[(methylamino)carbonyl]-3-pyridinyl]oxy]phenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 827043-31-2 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, N-[4-(4-pyridinyloxy)phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	21.55	287.78

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.12	-3.12

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 21:09:04 ON 23 OCT 2007